ReviewAnnals of translational medicine2017
Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers.
Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The Role ofMedicina (Kaunas, Lithuania) · 2020Trial
- Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.Cell death & disease · 2025Article
- Mechanism of ABCD3 inhibiting colorectal cancer progression by regulating Wnt/β-catenin.Molecular biology reports · 2025Article
- Elucidating the Mechanisms of Astragalus Membranaceus in Colorectal Cancer Patients through Bioinformatics Analysis.Current medicinal chemistry · 2025Article
- MMP-9-dependent proteolysis of the histone H3 N-terminal tail: a critical epigenetic step in driving oncogenic transcription and colon tumorigenesis.Molecular oncology · 2024Article
- Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis.Journal of medicine and life · 2024Review
- Article
- Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells.Molecular therapy. Nucleic acids · 2022Article
- Epigenetic-related Effects of COVID-19 on Human Cells.Infectious disorders drug targets · 2022Article
- Association between ERCC1 Gene Polymorphism (rs11615) and Colorectal Cancer Susceptibility: A Meta-Analysis of Medical Image Fusion and Safety Applications.Computational and mathematical methods in medicine · 2022Article
- MGP promotes CD8International journal of biological sciences · 2022Article
- DNA Methylation Profiling of MYC, SMAD2/3 and DNMT3A in Colorectal Cancer.Oman medical journal · 2021Review
- VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer.Molecular oncology · 2021Article
- Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay.Clinical epigenetics · 2021Article
- LAT1 and ASCT2 Related microRNAs as Potential New Therapeutic Agents against Colorectal Cancer Progression.Biomedicines · 2021Review
- Integrative Transcriptomic Network Analysis of Butyrate Treated Colorectal Cancer Cells.Cancers · 2021Article
- Candidate Molecular Biomarkers for the Non- Invasive Detection of Colorectal Cancer using Gene Expression Profiling.Iranian journal of pathology · 2021Article
- Decylubiquinone Inhibits Colorectal Cancer Growth Through Upregulating Sirtuin2.Frontiers in pharmacology · 2021Article
- Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.Cell death & disease · 2020Article
- Combining old and new strategies for colorectal cancer screening.Annals of translational medicine · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most common cancers worldwide and the second leading cause of cancer-related mortality in western countries. Despite the high incidence, treatment options for advanced CRC remain limited and unsuccessful, resulting in a poor prognosis. Therefore, novel accurate diagnostic, prognostic and predictive biomarkers are clearly and urgently needed to detect advanced colon polyps and early stage CRC and to identify the most effective treatments for specific CRC patients. CRC is known to develop from early premalignant lesions to full blown cancer via a multi-step process involving a series of genetic mutations that accumulate over time. Recent improvement of our understanding of CRC biology and advances in genomic technologies has led to the identification of a variety of epigenetic alterations strongly involved in cancer initiation and progression. Among the epigenetic marks implicated in CRC the most widely studied are the global DNA hypomethylation, the promoter hypermethylation and the miRNAs dysregulations. Many evidence exist that such tumour associated alterations may serve as new potential biomarkers. Moreover, due the non-invasive, objective, and potential reproducible assessment, circulating epigenetic biomarkers have reached increasing attentions in the last few years. In this review, we attempt to analyze the existing most recent literature on the role of circulating DNA methylations and miRNAs alterations in CRC diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.